

REMARKS

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

May 3, 2002

Kristina Bieker Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

F:\04585\04585.00200R Supplemental Reply to Examiner's Action.wpd

Version with markings to show changes made

132. (Amended) A method for inducing acetylcholine receptor synthesis in a cell, comprising contacting said cell with a polypeptide which comprises an epidermal growth factor-like domain, said domain comprising an amino acid sequence set forth in [selected from the group] consisting of] SEQ ID NO: 152 [151, 152, 188, 189, and 190], or said domain comprising an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of [SEQ ID NO: 154,] SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, and SEQ ID NO: 159, wherein said polypeptide is administered in an amount sufficient to stimulate synthesis of acetylcholine receptors in said cell.

138. (Twice Amended) The method of claim 132, wherein said epidermal growth factor-like domain comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of [SEQ ID NO: 154,] SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, and SEQ ID NO: 159.

141. (Amended) The method of claim 132, wherein said epidermal growth factor-like domain comprises an amino acid sequence set forth in [SEQ ID NO: 151,] SEQ ID NO: 152 [, or SEQ ID NO: 190].

142. The method of claim 132, wherein said polypeptide binds the p185^{erbB2} receptor.

143. The method of claim 132, wherein said polypeptide is a recombinant polypeptide.

Pending Claims

132. A method for inducing acetylcholine receptor synthesis in a cell, comprising contacting said cell with a polypeptide which comprises an epidermal growth factor-like domain, said domain comprising an amino acid sequence set forth in SEQ ID NO: 152, or said domain comprising an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, and SEQ ID NO: 159, wherein said polypeptide is administered in an amount sufficient to stimulate synthesis of acetylcholine receptors in said cell.

138. The method of claim 132, wherein said epidermal growth factor-like domain comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, and SEQ ID NO: 159.

141. The method of claim 132, wherein said epidermal growth factor-like domain comprises an amino acid sequence set forth in SEQ ID NO: 152.

142. The method of claim 132, wherein said polypeptide binds the p185^{erbB2} receptor.

143. The method of claim 132, wherein said polypeptide is a recombinant polypeptide.